Guanhao Biotech Co.,Ltd. (SHE:300238)

Market Cap	2.94B -41.7%
Revenue (ttm)	386.40M +1.5%
Net Income	19.64M -29.6%
EPS	0.07 -31.6%
Shares Out	265.16M
PE Ratio	153.48
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,156,903
Open	11.15
Previous Close	11.08
Day's Range	10.72 - 11.36
52-Week Range	10.19 - 18.85
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 535
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300238

Financial Performance

In 2025, Guanhao Biotech's revenue was 387.75 million, an increase of 2.72% compared to the previous year's 377.48 million. Earnings were 24.35 million, a decrease of -11.20%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 4, 2026

Data Sources Report a data error